0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of JAMA Neurology |

In This Issue of JAMA Neurology FREE

JAMA Neurol. 2013;70(4):434-435. doi:10.1001/jamaneurol.2013.2187.
Text Size: A A A
Published online

CEREBROVASCULAR EFFECTS OF APOLIPOPROTEIN E: IMPLICATIONS FOR ALZHEIMER DISEASE

ZlokovicArticle reviews β-amyloid–independent and β-amyloid–dependent cerebrovascular effects of apolipoprotein E as well as isoform-specific interactions of apolipoprotein E with low-density lipoprotein receptor-related protein 1 on brain vascular cells.

PEDIATRIC INTRACEREBRAL HEMORRHAGE: ACUTE SYMPTOMATIC SEIZURES AND EPILEPSY

To define the incidence of and explore risk factors for seizures and epilepsy in children with spontaneous intracerebral hemorrhage (ICH), Beslow and colleaguesArticle conducted a prospective cohort study of 73 pediatric subjects with spontaneous ICH, including 20 perinatal and 53 childhood subjects. Editorial perspective is provided by Geoffrey L. Heyer, MD, and E. Steve Roach, MDArticle.

WHITE MATTER HYPERINTENSITIES AND CEREBRAL AMYLOIDOSIS: NECESSARY AND SUFFICIENT FOR CLINICAL EXPRESSION OF ALZHEIMER DISEASE?

Provenzano and colleaguesArticle collected data from the Alzheimer Disease Neuroimaging Initiative public database to determine the impact of white matter hyperintensities and Pittsburgh Compound B positron-emission tomography–derived amyloid positivity on the clinical expression of Alzheimer disease. Editorial perspective is provided by Karen M. Rodrigue, PhDArticle.

EVALUATION OF POTENTIAL INFECTIVITY OF ALZHEIMER AND PARKINSON DISEASE PROTEINS IN RECIPIENTS OF CADAVER-DERIVED HUMAN GROWTH HORMONE

Irwin and colleaguesArticle examine evidence for human-to-human transmission of Alzheimer disease, Parkinson disease, and related neurodegenerative disease–associated proteins in cadaveric human growth hormone recipients.

NATALIZUMAB THERAPY FOR HIGHLY ACTIVE PEDIATRIC MULTIPLE SCLEROSIS

In a retrospective study, Kornek and coauthorsArticle report the use of natalizumab therapy for highly active pediatric multiple sclerosis.

Place holder to copy figure label and caption

Graphic Jump LocationImage not available.

Clinical course of pediatric patients with multiple sclerosis before and during natalizumab (NA) therapy. Patient numbers are given on the left side of the panel. *Patient 17 received interferon beta (IFN) plus methylprednisolone (MP) intravenously every 3 months. GA indicates glatiramer acetate.

INCIDENCE OF AMYOTROPHIC LATERAL SCLEROSIS AMONG AMERICAN INDIANS AND ALASKA NATIVES

To estimate the incidence and prevalence of amyotrophic lateral sclerosis and motor neuron disease for American Indian and Alaska Native people, Gordon and coworkersArticle analyzed electronic records separately for the calendar years 2002-2009 using inpatient and outpatient visit data from the Indian Health Service.

AUTOSOMAL DOMINANT SPASTIC PARAPLEGIAS: A REVIEW OF 89 FAMILIES RESULTING FROM A PORTUGUESE SURVEY

In a retrospective medical record review, Loureiro et alArticle describe the clinical, genetic, and epidemiological features of Portuguese families with autosomal dominant hereditary spastic paraplegias.

THE AGING BRAIN AND COGNITION: CONTRIBUTION OF VASCULAR INJURY AND AΒ TO MILD COGNITIVE DYSFUNCTION

Marchant and coauthorsArticle examine the relationship between neuroimaging measures of vascular brain injury and brain β-amyloid deposition and their associations with cognition in elderly individuals.

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption

Graphic Jump LocationImage not available.

Clinical course of pediatric patients with multiple sclerosis before and during natalizumab (NA) therapy. Patient numbers are given on the left side of the panel. *Patient 17 received interferon beta (IFN) plus methylprednisolone (MP) intravenously every 3 months. GA indicates glatiramer acetate.

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

450 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs